Transdermal Specialties Global, Inc.
Needle-free transdermal insulin patch using ultrasound.
Website: https://u-strip.com
Cover Block
| Attribute | Value |
|---|---|
| Name | Transdermal Specialties Global, Inc. |
| Tagline | Needle-free transdermal insulin patch using ultrasound. |
| Headquarters | Frederick, MD, United States |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Founding Team | Solo Founder (Bruce K. Redding Jr.) |
Links
- Website: https://u-strip.com/
- LinkedIn: https://www.linkedin.com/company/transdermal-specialties-global-inc/
Data Accuracy: GREEN -- Website URL confirmed by company sources; LinkedIn page is a standard corporate profile.
What an Investor Needs First
Transdermal Specialties Global is a pre-revenue biotech venture developing a needle-free insulin patch, a proposition that remains compelling for its potential to address patient non-compliance and discomfort in a massive chronic disease market, but its current viability is clouded by a 2021 bankruptcy filing and a lack of recent operational momentum. The company was founded by Bruce K. Redding Jr., a former NASA mission specialist who holds over 60 patents, and its core technology, the U-Strip™, uses ultrasound to temporarily expand skin pores for transdermal delivery of large-molecule drugs like insulin [Drug Development & Delivery, 2016] [BioBuzz]. The company's historical claims include a production capacity exceeding one million patches per week at a facility in Charlotte, North Carolina, and a pipeline of over 175 compounds [Drug Development & Delivery, 2016]. No funding rounds, customers, or strategic partnerships have been publicly disclosed, and the business model appears oriented toward eventual B2B licensing or partnership with larger pharmaceutical entities. The key near-term milestone, according to the company's website, is the readiness of a closed-loop system for clinical trials in 2026, though this timeline is unverified by independent sources [company website]. Investors should watch for any evidence of post-bankruptcy restructuring, new capital infusion, or validated progress toward clinical trials as the primary signals for a potential revival of the venture.
Data Accuracy: YELLOW -- Key historical claims are sourced from a single 2016 trade publication interview; bankruptcy and relocation are confirmed.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Founding Team | Solo Founder |
Inside the Company
Transdermal Specialties Global, Inc. (TSG) is a biotechnology company incorporated in Maryland, focused on developing needle-free transdermal drug delivery systems. The company's public narrative centers on its patented U-Strip™ technology, which uses ultrasound to facilitate the delivery of large-molecule drugs like insulin through the skin. Its headquarters are listed in Frederick, Maryland, following a relocation from Charlotte, North Carolina, announced in October 2020 [PRWeb, October 2020].
The company was founded by Bruce K. Redding Jr., a former NASA mission specialist who is listed as the inventor on numerous patents related to transdermal delivery [Justia Patents Search]. Public milestones are sparse and dated. A 2016 executive interview outlined plans for Phase III clinical trials for an insulin patch and claimed a production capacity exceeding one million patches per week at a Charlotte plant [Drug Development & Delivery, 2016]. The most recent public corporate action was a voluntary Chapter 11 bankruptcy filing on May 19, 2021 [PacerMonitor, 2021].
No subsequent funding rounds, customer announcements, or trial result publications from major medical or business outlets have been identified post-2021. The company's website remains active, with a blog post from February 2024 discussing a "new five-day transdermal insulin patch" and referencing a closed-loop system targeted for clinical trials in 2026 [company website, 2024]. However, the lack of independent verification for these claims and the 2021 bankruptcy filing create a significant gap in the operational timeline.
Data Accuracy: YELLOW -- Key entity facts (HQ, bankruptcy) are confirmed by public records; founder patent background is corroborated. Operational claims (capacity, trials) are from a single 2016 trade interview and unverified company statements.
Under the Hood
The company's core innovation is the U-Strip™, a needle-free transdermal patch designed to deliver insulin using low-frequency ultrasound. The system aims to create a non-invasive alternative to injections for managing type 1 and type 2 diabetes [Drug Development & Delivery, 2016]. The patented technology uses ultrasound to temporarily expand skin pores, allowing the transdermal delivery of large-molecule drugs like insulin, which has historically been a significant technical barrier [Drug Development & Delivery, 2016].
Publicly available details on the product's current state are limited. A 2016 interview cited a production capacity of over one million patches per week at a facility in Charlotte, North Carolina [Drug Development & Delivery, 2016]. The company's website states an ambition to have a closed-loop U-Strip™ system ready for clinical trials in 2026, though this is an unverified roadmap claim [company website]. Beyond insulin, the company has claimed a pipeline of over 175 compounds for potential transdermal delivery, including applications for central nervous system disorders [Drug Development & Delivery, 2016].
Data Accuracy: YELLOW -- Product claims are sourced from a 2016 trade interview and an undated company website, with no recent independent verification. The founder's patent portfolio is confirmed [Justia Patents Search].
Market Research and Opportunity
The addressable market for non-invasive drug delivery, particularly for chronic conditions like diabetes, is defined by a persistent patient demand for alternatives to daily injections and the high economic burden of disease management.
Third-party market sizing specific to needle-free insulin delivery is not available in the cited sources. For context, the global diabetes care devices market, which includes insulin pens, pumps, and syringes, was valued at approximately $30.7 billion in 2022 and is projected to grow to $45.2 billion by 2030, according to a Grand View Research report [Grand View Research, 2023]. The transdermal drug delivery systems segment within this broader market was valued at an estimated $6.5 billion in 2022 [Grand View Research, 2023].
Key demand drivers for a solution like the U-Strip™ are well-documented. The global prevalence of diabetes continues to rise, with the International Diabetes Federation reporting 537 million adults living with diabetes in 2021, a number projected to increase to 643 million by 2030 [IDF Diabetes Atlas, 2021]. Patient adherence remains a significant challenge; studies indicate needle phobia and the inconvenience of frequent injections contribute to non-compliance, which can lead to worse health outcomes and higher long-term costs [Journal of Diabetes Science and Technology, 2018].
| Metric | Value |
|---|---|
| Global Diabetes Care Devices Market (2022) | $30.7B |
| Projected Market (2030) | $45.2B |
| Transdermal Delivery Systems Segment (2022) | $6.5B |
Data Accuracy: YELLOW -- Market sizing is based on analogous, third-party industry reports. Company-specific SAM/SOM and pipeline validation are not publicly available.
Competition and Substitutes
Transdermal Specialties Global (TSG) operates in a high-stakes, capital-intensive segment where its needle-free insulin patch concept faces established incumbents and a new wave of non-invasive delivery challengers, though no direct named competitors are confirmed in public sources.
The primary competitive set for TSG's U-Strip™ consists of three segments. First, the dominant incumbents are the large pharmaceutical and medical device companies that manufacture and distribute traditional insulin via syringes, pens, and pumps, such as Novo Nordisk, Eli Lilly, and Medtronic. Second, a growing cohort of challengers is developing alternative non-invasive insulin delivery methods, including inhaled insulin (like MannKind's Afrezza), oral insulin formulations, and other transdermal approaches using microneedles or iontophoresis. Third, adjacent substitutes include emerging diabetes management technologies, such as continuous glucose monitors (CGMs) from Dexcom and Abbott.
TSG's claimed defensible edge rests entirely on its proprietary U-Strip™ technology and the associated intellectual property. The company's patents around using ultrasound to expand skin pores for large-molecule delivery, including insulin, represent a technical barrier to entry [Justia Patents Search]. Founder Bruce Redding's background as a named inventor on numerous patents supports this claim [BioBuzz]. However, this edge is highly perishable. It is contingent on the company's ability to fund and complete late-stage clinical trials to demonstrate safety and efficacy, a process it has not publicly achieved. Without the capital to advance through regulatory milestones, the patent portfolio alone does not create a commercial moat.
The company's most significant exposure is its lack of commercial infrastructure and recent financial distress. It filed for bankruptcy in May 2021 [PacerMonitor, 2021], which severely limits its ability to compete on capital, talent acquisition, or partnership development. This financial position leaves it vulnerable to well-funded competitors that can outpace its R&D.
Data Accuracy: YELLOW -- Competitive analysis is inferred from the broader diabetes care market due to a lack of named, direct competitors in sources. TSG's patent position is confirmed, but its operational and financial status post-2021 is based on a single public filing.
Opportunity
The core opportunity for Transdermal Specialties Global is to establish the first commercially viable, needle-free transdermal delivery system for large-molecule drugs, beginning with a multi-billion dollar addressable market in diabetes care.
The headline opportunity is the creation of a new drug delivery category standard. If the company's U-Strip™ technology can reliably deliver insulin and other biologics without needles, it would represent a fundamental shift in chronic disease management. The plausibility of this outcome rests on the technical claim, cited in a 2016 trade interview, that the platform can deliver molecules up to 125,000 Daltons transdermally [Drug Development & Delivery, 2016].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Insulin Patch Commercialization | The company successfully brings its five-day insulin patch to market for type 1 and 2 diabetes patients. | FDA clearance following a completed Phase III clinical trial. | The company has stated its closed-loop system is targeted for clinical trials in 2026 [company website]. |
| Pharmaceutical Partnership & Licensing | TSG transitions from a product company to a platform licensor, partnering with large pharma to deliver their proprietary biologics. | A strategic research arrangement or licensing deal with a named pharmaceutical company. | The company's 2016 interview mentioned "strategic research arrangements" and a drug screening program [Drug Development & Delivery, 2016]. |
Data Accuracy: ORANGE -- Key opportunity claims (pipeline, technical capabilities) are sourced from a single 2016 trade interview and un-dated website material. The 2026 trial target and bankruptcy filing are not reconciled in public information.
Sources
- [Drug Development & Delivery, 2016] Executive Interview: Transdermal Specialties - A New Dimension in Transdermal Drug Delivery | https://drug-dev.com/executive-interview-transdermal-specialties-a-new-dimension-in-transdermal-drug-delivery/
- [BioBuzz] In Conversation: Bruce K. Redding Jr. | https://biobuzz.io/in-conversation-bruce-k-redding-jr-ceo-of-transdermal-specialties-global/
- [PRWeb, October 2020] Transdermal Specialties Global (TSG) announces that it has relocated to Frederick MD | https://www.prweb.com/releases/Transdermal_Specialties_Global_TSG_announces_that_it_has_relocated_to_Frederick_MD/prweb17447086.htm
- [Justia Patents Search] Bruce Redding Inventions, Patents and Patent Applications - Justia Patents Search | https://patents.justia.com/inventor/bruce-redding
- [PacerMonitor, 2021] Transdermal Specialties Global, Inc. Bankruptcy | https://www.pacermonitor.com/public/case/40302714/Transdermal_Specialties_Global,_Inc
- [company website] Leadership | https://u-strip.com/leadership/
- [company website, 2024] New Five-Day Transdermal Insulin Patch | https://u-strip.com/2024/02/28/new-five-day-transdermal-insulin-patch/
- [Drug Development & Delivery] Transdermal Specialties Announces Success of Insulin Patch Clinical Trial | https://drug-dev.com/transdermal-specialties-announces-success-of-insulin-patch-clinical-trial/
- [Grand View Research, 2023] Diabetes Care Devices Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/diabetes-care-devices-market
- [IDF Diabetes Atlas, 2021] IDF Diabetes Atlas 10th edition | https://diabetesatlas.org/atlas/tenth-edition/
- [Journal of Diabetes Science and Technology, 2018] Needle Phobia and Adherence in Diabetes | https://journals.sagepub.com/doi/10.1177/1932296818755325
Articles about Transdermal Specialties Global, Inc.
- A Transdermal Patch for Insulin, Without the Needle — Transdermal Specialties Global's ultrasound-based U-Strip aimed to replace injections for millions with diabetes, but a 2021 bankruptcy filing clouds its path to patients.